BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25027585)

  • 1. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
    Lin LY; Huang CC; Chen JS; Wu TC; Leu HB; Huang PH; Chang TT; Lin SJ; Chen JW
    Cardiovasc Diabetol; 2014 Jul; 13():111. PubMed ID: 25027585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
    Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
    PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
    Oikonomou E; Siasos G; Zaromitidou M; Hatzis G; Mourouzis K; Chrysohoou C; Zisimos K; Mazaris S; Tourikis P; Athanasiou D; Stefanadis C; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Feb; 238(2):159-64. PubMed ID: 25525743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
    Saku K; Zhang B; Noda K;
    Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
    Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
    J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: the newest HMG-CoA reductase inhibitor.
    Watson KE
    Rev Cardiovasc Med; 2010; 11(1):26-32. PubMed ID: 20495513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
    Poolsup N; Suksomboon N; Wongyaowarat K; Rungkanchananon B; Niyomrat P; Kongsuwan S
    J Clin Pharm Ther; 2012 Apr; 37(2):166-72. PubMed ID: 21585411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
    Yoshida H; Shoda T; Yanai H; Ikewaki K; Kurata H; Ito K; Furutani N; Tada N; Witztum JL; Tsimikas S
    Atherosclerosis; 2013 Jan; 226(1):161-4. PubMed ID: 23174369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
    Jaumdally RJ; Goon PK; Varma C; Blann AD; Lip GY
    J Intern Med; 2010 Apr; 267(4):385-93. PubMed ID: 19754853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
    Sakabe K; Fukuda N; Fukuda Y; Wakayama K; Nada T; Morishita S; Shinohara H; Tamura Y
    Int J Cardiol; 2008 Mar; 125(1):136-8. PubMed ID: 17400311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study.
    Tarim BA; Fici F; Tengiz I; Avunduk S; Ozcan Y; Faikoglu G; Ari E; Robles NR; Grassi G
    Yonsei Med J; 2023 Mar; 64(3):175-180. PubMed ID: 36825343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
    Kurata T; Miyazaki K; Kozuki M; Panin VL; Morimoto N; Ohta Y; Nagai M; Ikeda Y; Matsuura T; Abe K
    Brain Res; 2011 Jan; 1371():161-70. PubMed ID: 21112317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.